

# Angelo Antonini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7679200/publications.pdf>

Version: 2024-02-01

603  
papers

34,963  
citations

2975

93  
h-index

6836

155  
g-index

623  
all docs

623  
docs citations

623  
times ranked

25088  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Oscillatory EEG-TMS Reactivity in Parkinson Disease. <i>Journal of Clinical Neurophysiology</i> , 2023, 40, 263-268.   | 1.7  | 3         |
| 2  | Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians. <i>Movement Disorders</i> , 2022, 37, 182-189.  | 3.9  | 18        |
| 3  | A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. <i>Journal of Neurology</i> , 2022, 269, 1335-1352.  | 3.6  | 23        |
| 4  | Impairment of human dopaminergic neurons at different developmental stages by perfluoro-octanoic acid (PFOA) and differential human brain areas accumulation of perfluoroalkyl chemicals. <i>Environment International</i> , 2022, 158, 106982.            | 10.0 | 32        |
| 5  | Early Compensatory Mechanisms in <i>LRRK2</i> Mutation Carriers. <i>Movement Disorders</i> , 2022, 37, 662-663.  | 3.9  | 0         |
| 6  | Subthalamic deep brain stimulation in Parkinson's disease with <i>SNCA</i> mutations: Based on the follow-up to 10 years. <i>Brain and Behavior</i> , 2022, 12, e2503.   | 2.2  | 7         |
| 7  | Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. <i>BMC Neurology</i> , 2022, 22, 35.  | 1.8  | 12        |
| 8  | Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries. <i>Neurology and Therapy</i> , 2022, 11, 303-318.   | 3.2  | 6         |
| 9  | Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus. <i>Npj Parkinson's Disease</i> , 2022, 8, 17.   | 5.3  | 7         |
| 10 | Effect of Intensive Rehabilitation Program in Thermal Water on a Group of People with Parkinson's Disease: A Retrospective Longitudinal Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 368.  | 2.0  | 4         |
| 11 | Antiphospholipid-Related Chorea: Two Case Reports and Role of Metabolic Imaging. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 516-521.   | 1.5  | 4         |
| 12 | Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Trial. <i>Trials</i> , 2022, 23, 107.                 | 0.8  | 0         |
| 13 | Level I <i>PD-MCI</i> Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 479-483.  | 1.5  | 11        |
| 14 | Development and Validation of Automated <i>Magnetic Resonance</i> Parkinsonism Index 2.0 to Distinguish <i>Progressive Supranuclear Palsy</i> from <i>Parkinson's Disease</i> . <i>Movement Disorders</i> , 2022, 37, 1272-1281.                           | 3.9  | 17        |
| 15 | Gender gap in deep brain stimulation for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 47.  | 5.3  | 22        |
| 16 | Action Selection and Motor Decision Making: Insights from Transcranial Magnetic Stimulation. <i>Brain Sciences</i> , 2022, 12, 639.  | 2.3  | 2         |
| 17 | Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities. <i>Journal of Personalized Medicine</i> , 2022, 12, 813.  | 2.5  | 4         |
| 18 | Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial. <i>Neurology and Therapy</i> , 2022, 11, 1409-1425. | 3.2  | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Neurocognitive correlates of numerical abilities in Parkinson's disease. <i>Neurological Sciences</i> , 2022, 43, 5313-5322.   | 1.9 | 1         |
| 20 | Spotlight on non-motor symptoms and Covid-19. <i>International Review of Neurobiology</i> , 2022, , .  | 2.0 | 0         |
| 21 | European Academy of Neurology/Movement Disorder Society's European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies. <i>Movement Disorders</i> , 2022, 37, 1360-1374.                  | 3.9 | 49        |
| 22 | European Academy of Neurology/Movement Disorder Society's European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. <i>European Journal of Neurology</i> , 2022, 29, 2580-2595.       | 3.3 | 22        |
| 23 | A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , 2021, 36, 681-689.                  | 3.9 | 22        |
| 24 | Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , 2021, 28, 1752-1758.                                      | 3.3 | 45        |
| 25 | Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 323-335.  | 2.8 | 21        |
| 26 | The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 448-454.                               | 3.6 | 16        |
| 27 | The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 3-12.   | 2.1 | 49        |
| 28 | The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. <i>Brain Communications</i> , 2021, 3, fcab180.  | 3.3 | 17        |
| 29 | Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease. <i>Current Neuropharmacology</i> , 2021, 19, 1618-1639. | 2.9 | 9         |
| 30 | TaSCA, an Agile Survey on Chemosensory Impairments for Self-Monitoring of COVID-19 Patients: A Pilot Study. <i>Frontiers in Neurology</i> , 2021, 12, 633574.  | 2.4 | 1         |
| 31 | Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 322-340.            | 1.5 | 7         |
| 32 | Parkinson's Disease and Post-COVID-19 Syndrome: The Parkinson's Long-COVID Spectrum. <i>Movement Disorders</i> , 2021, 36, 1287-1289.  | 3.9 | 51        |
| 33 | The impact of COVID-19 on palliative care for people with Parkinson's and response to future pandemics. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 615-623.   | 2.8 | 15        |
| 34 | Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 124-132.   | 2.2 | 22        |
| 35 | Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. <i>Npj Parkinson's Disease</i> , 2021, 7, 43.   | 5.3 | 32        |
| 36 | Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies. <i>Movement Disorders</i> , 2021, 36, 1781-1791.  | 3.9 | 40        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on "Off"-time in Patients with Advanced Parkinson's Disease: A Systematic Review. <i>Advances in Therapy</i> , 2021, 38, 2854-2890.   | 2.9 | 41        |
| 38 | Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 48.  | 5.3 | 23        |
| 39 | Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2303-2313.   | 3.9 | 26        |
| 40 | Comparison of self-reported symptoms and psychophysical tests in coronavirus disease 2019 (COVID-19) subjects experiencing long-term olfactory dysfunction: a 6-month follow-up study. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1592-1595. | 2.8 | 19        |
| 41 | Movement perception of the tonic vibration reflex is abnormal in functional limb weakness. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 1-6.   | 2.2 | 6         |
| 42 | Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. <i>Journal of Personalized Medicine</i> , 2021, 11, 623.  | 2.5 | 18        |
| 43 | Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 186-194.  | 2.2 | 26        |
| 44 | Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile. <i>Journal of Personalized Medicine</i> , 2021, 11, 773.  | 2.5 | 20        |
| 45 | Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown. <i>BMC Neurology</i> , 2021, 21, 332.   | 1.8 | 25        |
| 46 | Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers Study Protocol for a Multicentre, Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2021, 12, 673893.                                      | 2.4 | 7         |
| 47 | The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1309-1323.   | 2.8 | 8         |
| 48 | Consensus on the treatment of dysphagia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120008.  | 0.6 | 23        |
| 49 | Reduced Effective Connectivity in the Motor Cortex in Parkinson's Disease. <i>Brain Sciences</i> , 2021, 11, 1200.  | 2.3 | 6         |
| 50 | Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy". <i>Movement Disorders</i> , 2021, 36, 2208-2209.   | 3.9 | 0         |
| 51 | Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 128.   | 3.8 | 38        |
| 52 | Alpha-synuclein pathology and enteric glia in advanced Parkinson's disease: A study from gastrointestinal biopsies. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119460.  | 0.6 | 2         |
| 53 | The epsilon (early Parkinson with L-dopa/DDCi and opicapone) study in early Parkinson's disease: Design and rationale of a phase III, double-blind, randomized, placebo-controlled study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119422.        | 0.6 | 1         |
| 54 | Study design to assess the effect of opicapone on levodopa pharmacokinetics in different levodopa-optimized treatment regimens in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119438.                                  | 0.6 | 0         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Education on palliative care for Parkinson patients: development of the "Best care for people with late-stage Parkinson's disease" curriculum toolkit. BMC Medical Education, 2021, 21, 538.  | 2.4  | 8         |
| 56 | Challenges in advanced treatments in Parkinson's disease. Journal of the Neurological Sciences, 2021, 429, 117949.  | 0.6  | 0         |
| 57 | Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations. Journal of the Neurological Sciences, 2021, 429, 119450.   | 0.6  | 0         |
| 58 | Adoption (early levodopa with opicapone in Parkinson's patients with motor fluctuations) study in Parkinson's disease: Design and rationale of a randomized prospective, open-label exploratory trial. Journal of the Neurological Sciences, 2021, 429, 119423. | 0.6  | 0         |
| 59 | The ocean (opicapone effect on motor fluctuations and associated pain) study in Parkinson's disease: Design and rationale of a randomized double-blind placebo-controlled trial. Journal of the Neurological Sciences, 2021, 429, 119424.                       | 0.6  | 0         |
| 60 | Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. Parkinsonism and Related Disorders, 2021, 92, 59-66.                                       | 2.2  | 23        |
| 61 | The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. Frontiers in Neurology, 2021, 12, 754016.   | 2.4  | 7         |
| 62 | Remote Evaluation of Parkinson's Disease Using a Conventional Webcam and Artificial Intelligence. Frontiers in Neurology, 2021, 12, 742654.   | 2.4  | 13        |
| 63 | Quantification of Brain $\beta^2$ -Amyloid Load in Parkinson's Disease With Mild Cognitive Impairment: A PET/MRI Study. Frontiers in Neurology, 2021, 12, 760518.   | 2.4  | 4         |
| 64 | Fractal Analysis of Lower Back Acceleration Profiles in balance tasks. , 2021, 2021, 7381-7384.   |      | 2         |
| 65 | Deep brain stimulation for monogenic Parkinson's disease: a systematic review. Journal of Neurology, 2020, 267, 883-897.  | 3.6  | 31        |
| 66 | Validation of the Movement Disorder Society Criteria for the Diagnosis of 4 $\alpha$ -Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.  | 3.9  | 37        |
| 67 | New routes of dopaminergic drug delivery in patients with Parkinson's disease. Lancet Neurology, The, 2020, 19, 105-106.  | 10.2 | 0         |
| 68 | Differences in cognitive profiles between Lewy body and Parkinson's disease dementia. Journal of Neural Transmission, 2020, 127, 323-330.   | 2.8  | 18        |
| 69 | Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease. Brain Stimulation, 2020, 13, 1697-1705.  | 1.6  | 36        |
| 70 | Patient-centred management of Parkinson's disease. Lancet Neurology, The, 2020, 19, 887-888.  | 10.2 | 2         |
| 71 | Incentive-driven decision-making networks in de novo and drug-treated Parkinson's disease patients with impulsive-compulsive behaviors: A systematic review of neuroimaging studies. Parkinsonism and Related Disorders, 2020, 78, 165-177.                     | 2.2  | 6         |
| 72 | Moving towards home-based community-centred integrated care in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 78, 21-26.  | 2.2  | 27        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Prevalence of Extrapyrarnidal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism. <i>Frontiers in Neurology</i> , 2020, 11, 593143.  | 2.4  | 7         |
| 74 | Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology. <i>Frontiers in Neurology</i> , 2020, 11, 575975.  | 2.4  | 32        |
| 75 | Reply to: "Concerns Raised by Publication of Antonini et al., "Outcome of Parkinson Disease Patients Affected by Covid-19", <i>Movement Disorders</i> , 2020, 35, 1298-1298.  | 3.9  | 3         |
| 76 | Application of the "5-2-1" screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. <i>Neurodegenerative Disease Management</i> , 2020, 10, 309-323.   | 2.2  | 33        |
| 77 | Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 920-929.  | 1.5  | 45        |
| 78 | Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762. | 1.5  | 31        |
| 79 | COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. <i>Npj Parkinson's Disease</i> , 2020, 6, 18.   | 5.3  | 120       |
| 80 | Data-assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, e043593.  | 0.8  | 1         |
| 81 | The reliability of a deep learning model in external memory clinic MRI data: A multicohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, e042969.  | 0.8  | 0         |
| 82 | Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2899-2912.  | 2.2  | 9         |
| 83 | Anatomy and Connectivity of the Subthalamic Nucleus in Humans and Non-human Primates. <i>Frontiers in Neuroanatomy</i> , 2020, 14, 13.  | 1.7  | 48        |
| 84 | A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 687-694.  | 1.9  | 36        |
| 85 | Immunitization therapies for Parkinson's disease: state of the art and considerations for future clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 685-695.   | 4.1  | 21        |
| 86 | The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , 2020, 66, 101714.   | 11.6 | 90        |
| 87 | Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey. <i>Journal of Neural Transmission</i> , 2020, 127, 875-879.   | 2.8  | 10        |
| 88 | Dyskinesia Matters: But Not as Much as It Used to. <i>Movement Disorders</i> , 2020, 35, 900-901.   | 3.9  | 2         |
| 89 | Health care for chronic neurological patients after COVID-19. <i>Lancet Neurology</i> , The, 2020, 19, 562-563.   | 10.2 | 5         |
| 90 | Predictors of Response for "Off"-Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry. <i>Frontiers in Neurology</i> , 2020, 11, 419.  | 2.4  | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Comment on "The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis". <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 852-852.   | 1.9 | 5         |
| 92  | Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease. <i>Journal of Neurology</i> , 2020, 267, 1830-1841.   | 3.6 | 17        |
| 93  | The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2020, 127, 881-891.   | 2.8 | 8         |
| 94  | Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving a 2000mg Daily Dose of Levodopa. <i>Parkinson's Disease</i> , 2020, 2020, 1-11.   | 1.1 | 8         |
| 95  | Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020, 35, 976-983.  | 3.9 | 38        |
| 96  | The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.  | 3.9 | 31        |
| 97  | Outcome of Parkinson's Disease Patients Affected by COVID-19. <i>Movement Disorders</i> , 2020, 35, 905-908.  | 3.9 | 192       |
| 98  | Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population. <i>Neurological Sciences</i> , 2020, 41, 2929-2937.   | 1.9 | 3         |
| 99  | Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 361-372.  | 1.5 | 91        |
| 100 | Opicapone's added benefit as a first-line adjunctive therapy to levodopa and when used promptly for motor fluctuations in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e71-e72.   | 2.2 | 1         |
| 101 | Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020, 8, e16414.  | 3.7 | 33        |
| 102 | Efficacy, safety and patient's quality of life of long-term treatment with levodopa-carbidopa intestinal gel in advanced Parkinson's disease in Romania: Results from GLORIA observational study. <i>Romanian Journal of Neurology/ Revista Romana De Neurologie</i> , 2020, 19, 27-35. | 0.1 | 6         |
| 103 | Opicapone as first-line adjunctive levodopa treatment in Parkinson's disease patients with motor fluctuations: BIPARK-I and II combined post-hoc analysis. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e63.   | 2.2 | 0         |
| 104 | Efficacy of opicapone in different treatment regimens in Parkinson's disease patients with motor fluctuations. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e64-e65.   | 2.2 | 3         |
| 105 | Characteristics, treatment patterns and disease burden of people with Parkinson's disease in the Parkinson's disease real-world impact assessment (PRISM) study. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e86.   | 2.2 | 0         |
| 106 | Content validity of MANAGE-PD tool: Real-world evidence from PD patients in G7 countries. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e46-e47.  | 2.2 | 0         |
| 107 | Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease. <i>Postgraduate Medicine</i> , 2019, 131, 509-522.  | 2.0 | 24        |
| 108 | Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 1437-1445.  | 2.8 | 25        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. <i>Journal of Parkinson's Disease</i> , 2019, 9, 531-541.  | 2.8 | 30        |
| 110 | Dynamic functional connectivity changes associated with dementia in Parkinson's disease. <i>Brain</i> , 2019, 142, 2860-2872.   | 7.6 | 190       |
| 111 | The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 1327-1333.                                      | 3.3 | 22        |
| 112 | Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1203-1218.   | 2.4 | 29        |
| 113 | Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study. <i>Journal of Drug Assessment</i> , 2019, 8, 159-166.  | 2.2 | 8         |
| 114 | Reply: Dynamic functional connectivity changes in Lewy body disease. <i>Brain</i> , 2019, 142, e69-e69.   | 7.6 | 1         |
| 115 | Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116411.   | 0.6 | 6         |
| 116 | Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 972.  | 2.4 | 1         |
| 117 | Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019, 142, 3592-3604.  | 7.6 | 90        |
| 118 | Stridor in multiple system atrophy. <i>Neurology</i> , 2019, 93, 630-639.   | 1.1 | 86        |
| 119 | EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 353-365.   | 3.9 | 126       |
| 120 | Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. <i>Journal of Neurology</i> , 2019, 266, 2164-2176. | 3.6 | 42        |
| 121 | Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation. <i>Journal of Neural Transmission</i> , 2019, 126, 739-757.                   | 2.8 | 24        |
| 122 | A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.   | 3.9 | 73        |
| 123 | How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.   | 3.9 | 93        |
| 124 | Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 266.   | 2.4 | 8         |
| 125 | Dysphagia predicts poor outcome in late-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 73-81.   | 2.2 | 26        |
| 126 | Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?. <i>Movement Disorders</i> , 2019, 34, 816-819.  | 3.9 | 47        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309.                            | 2.4 | 30        |
| 128 | Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 211.                                      | 0.6 | 0         |
| 129 | Utilization of COMT inhibitors, dopamine agonists, and MAO-B inhibitors with levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients: Summary of phase 3 and real-world studies. <i>Journal of the Neurological Sciences</i> , 2019, 405, 29-30. | 0.6 | 0         |
| 130 | Efficacy of opicapone in Parkinson's disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 192.  | 0.6 | 0         |
| 131 | Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens". <i>Movement Disorders</i> , 2019, 34, 1930-1931.   | 3.9 | 2         |
| 132 | Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: Post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 203.                   | 0.6 | 0         |
| 133 | Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. <i>Neurodegenerative Disease Management</i> , 2019, 9, 39-46.   | 2.2 | 19        |
| 134 | A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2019, 15, 400-409.  | 0.8 | 60        |
| 135 | Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 57-64.   | 1.5 | 17        |
| 136 | Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. <i>European Journal of Neurology</i> , 2019, 26, 581.   | 3.3 | 23        |
| 137 | Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson's disease patients. <i>Brain Imaging and Behavior</i> , 2019, 13, 232-240.   | 2.1 | 24        |
| 138 | Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 421-430.  | 3.9 | 69        |
| 139 | Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. <i>Journal of Neurology</i> , 2018, 265, 1124-1137.  | 3.6 | 52        |
| 140 | Pain in Parkinson's disease: facts and uncertainties. <i>European Journal of Neurology</i> , 2018, 25, 917.   | 3.3 | 66        |
| 141 | Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. <i>Brain Stimulation</i> , 2018, 11, 867-874.  | 1.6 | 36        |
| 142 | Medical and surgical management of advanced Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 900-908.   | 3.9 | 124       |
| 143 | Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2018, 8, 161-170.  | 2.2 | 13        |
| 144 | Relevance of sleep quality on caregiver burden in Parkinson's disease. <i>Neurological Sciences</i> , 2018, 39, 835-839.  | 1.9 | 31        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 145 | DBS for Parkinson's disease with behavioural disturbances. <i>Lancet Neurology</i> , The, 2018, 17, 195-197.   | 10.2 | 5         |
| 146 | Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. <i>Neuromodulation</i> , 2018, 21, 532-540.  | 0.8  | 26        |
| 147 | Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. <i>Brain Stimulation</i> , 2018, 11, 904-912.  | 1.6  | 53        |
| 148 | Nutritional habits, risk, and progression of Parkinson disease. <i>Journal of Neurology</i> , 2018, 265, 12-23.  | 3.6  | 45        |
| 149 | Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age. <i>Movement Disorders</i> , 2018, 33, 99-107.   | 3.9  | 39        |
| 150 | <sc>USP</sc> 14 inhibition corrects an <i>in vivo</i> model of impaired mitophagy. <i>EMBO Molecular Medicine</i> , 2018, 10, .  | 6.9  | 69        |
| 151 | Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 229-237.   | 2.6  | 30        |
| 152 | Apomorphine infusion in advanced Parkinson disease. <i>Nature Reviews Neurology</i> , 2018, 14, 693-694.   | 10.1 | 12        |
| 153 | Regulation of ER-mitochondria contacts by Parkin via Mfn2. <i>Pharmacological Research</i> , 2018, 138, 43-56.   | 7.1  | 152       |
| 154 | Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial. <i>Trials</i> , 2018, 19, 492.                                       | 1.6  | 23        |
| 155 | First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. <i>European Journal of Neurology</i> , 2018, 25, 1255-1261.   | 3.3  | 25        |
| 156 | Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. <i>Journal of Neural Transmission</i> , 2018, 125, 1131-1135.   | 2.8  | 27        |
| 157 | Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. <i>Current Medical Research and Opinion</i> , 2018, 34, 2063-2073. | 1.9  | 152       |
| 158 | A decision support system based on rapid progression rules to enhance baseline evaluation of Parkinson's disease patients. , 2018, , .   |      | 1         |
| 159 | Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 14.  | 5.3  | 70        |
| 160 | A decision support system for Parkinson disease management: expert models for suggesting medication change. <i>Journal of Decision Systems</i> , 2018, 27, 164-172.  | 3.2  | 15        |
| 161 | Disease progression in Parkinson subtypes: the PPMI dataset. <i>Neurological Sciences</i> , 2018, 39, 1971-1976.   | 1.9  | 67        |
| 162 | Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 90-92.   | 2.2  | 44        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | The <scp>PRIAMO</scp> study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. <i>European Journal of Neurology</i> , 2017, 24, 788-795.         | 3.3 | 37        |
| 164 | Distribution and impact on quality of life of the pain modalities assessed by the Kingâ€™s Parkinsonâ€™s disease pain scale. <i>Npj Parkinson's Disease</i> , 2017, 3, 8.           | 5.3 | 27        |
| 165 | Mining motor symptoms UPDRS data of Parkinson's disease patients for the development of Hoehn and Yahr estimation decision support system. , 2017, , .                              |     | 1         |
| 166 | Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.  | 3.9 | 121       |
| 167 | Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.  | 3.9 | 179       |
| 168 | Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 113-117.                   | 2.2 | 18        |
| 169 | Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.  | 3.9 | 1,402     |
| 170 | Relationship between pain and motor and nonâ€™motor symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , 2017, 24, 974-980.                                      | 3.3 | 26        |
| 171 | Device-Aided Treatment Strategies in Advanced Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 453-474.  | 2.0 | 29        |
| 172 | Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 14, 734-740.             | 2.7 | 89        |
| 173 | Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 37-43.    | 2.2 | 44        |
| 174 | The role of highâ€™field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , 2017, 32, 510-525.                       | 3.9 | 92        |
| 175 | ICARUS study: prevalence and clinical features of impulse control disorders in Parkinsonâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 317-324. | 1.9 | 119       |
| 176 | Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 840-860.  | 0.5 | 38        |
| 177 | Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 13-20.                       | 2.2 | 149       |
| 178 | Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. <i>Movement Disorders</i> , 2017, 32, 1557-1565.                                       | 3.9 | 65        |
| 179 | Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 491-501.                    | 2.8 | 44        |
| 180 | Understanding and Treating Pain Syndromes in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 827-858.   | 2.0 | 26        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | PD_Manager: an mHealth platform for Parkinson's disease patient management. Healthcare Technology Letters, 2017, 4, 102-108.   | 3.3 | 66        |
| 182 | Cognitive impairment in multiple system atrophy. Movement Disorders, 2017, 32, 1338-1339.  | 3.9 | 19        |
| 183 | Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. ENeurologicalSci, 2017, 8, 44-53.   | 1.3 | 10        |
| 184 | Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. International Review of Neurobiology, 2017, 133, 389-415.   | 2.0 | 11        |
| 185 | Predicting rapid progression of Parkinson's Disease at baseline patients evaluation. , 2017, 2017, 3898-3901.  |     | 7         |
| 186 | An Observational Study of the Effect of Levodopa+Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. Advances in Therapy, 2017, 34, 1741-1752.  | 2.9 | 24        |
| 187 | Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists. World Neurosurgery, 2017, 99, 41-46.  | 1.3 | 45        |
| 188 | Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. European Radiology, 2017, 27, 2665-2675. | 4.5 | 66        |
| 189 | Brain structural profile of multiple system atrophy patients with cognitive impairment. Journal of Neural Transmission, 2017, 124, 293-302.  | 2.8 | 46        |
| 190 | Water-based vs. non-water-based physiotherapy for rehabilitation of postural deformities in Parkinson's disease: a randomized controlled pilot study. Clinical Rehabilitation, 2017, 31, 1107-1115.  | 2.2 | 37        |
| 191 | Non-motor symptoms (nms) improvement is correlated with baseline nms burden and improved quality of life (QoL) in levodopa-carbidopa intestinal gel (LCIG) treated parkinson's disease patients. Journal of the Neurological Sciences, 2017, 381, 98.              | 0.6 | 0         |
| 192 | Baseline characteristics that influence on-time improvement in levodopa-carbidopa intestinal gel-treated advanced Parkinson's disease patients in the GLORIA registry. Journal of the Neurological Sciences, 2017, 381, 187.                                       | 0.6 | 1         |
| 193 | A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. Journal of Parkinson's Disease, 2017, 7, 533-543.   | 2.8 | 45        |
| 194 | The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging. Frontiers in Aging Neuroscience, 2017, 9, 330.  | 3.4 | 26        |
| 195 | Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. Frontiers in Neurology, 2017, 8, 432.   | 2.4 | 50        |
| 196 | Peri-electrode edema after bilateral subthalamic deep brain stimulation for Parkinson's disease. Journal of Neurosurgical Sciences, 2017, 62, 103-105.   | 0.6 | 1         |
| 197 | Dopaminergic Medication Modulates Learning from Feedback and Error-Related Negativity in Parkinson's Disease: A Pilot Study. Frontiers in Behavioral Neuroscience, 2016, 10, 205.  | 2.0 | 10        |
| 198 | Globus pallidus internus deep brain stimulation for the treatment of status dystonicus in tardive dystonia. Acta Neurochirurgica, 2016, 158, 1789-1791.  | 1.7 | 12        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | tDCS effect on cognitive performance in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1253-1254.  | 3.9 | 6         |
| 200 | Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. <i>Journal of Neural Transmission</i> , 2016, 123, 1435-1442.                 | 2.8 | 61        |
| 201 | A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016, 23, 1255-1261.                         | 3.3 | 76        |
| 202 | Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 451-458.  | 2.1 | 23        |
| 203 | Apathy in Mild Parkinson's Disease: Neuropsychological and Neuroimaging Evidence. <i>Journal of Parkinson's Disease</i> , 2016, 6, 821-832.  | 2.8 | 28        |
| 204 | Design and Development of a Mobile Application to Explore Cognitive Skills in Parkinson's Disease Patients. <i>IFMBE Proceedings</i> , 2016, , 1150-1155.  | 0.3 | 1         |
| 205 | Anatomical profile of cognitive impairment in MSA. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e118.   | 2.2 | 0         |
| 206 | Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology</i> , 2016, 23, 1556-1565.  | 3.3 | 51        |
| 207 | 503 BRAF-V600 Mutation discordance in Primary and Metastatic Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, S246.  | 0.7 | 0         |
| 208 | 494 Heterogeneous mutational status of melanomas in multiple primary melanoma patients. <i>Journal of Investigative Dermatology</i> , 2016, 136, S244.   | 0.7 | 0         |
| 209 | Anatomical and functional correlates of persistent pain in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1854-1864.   | 3.9 | 57        |
| 210 | Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. <i>Movement Disorders</i> , 2016, 31, 530-537.   | 3.9 | 88        |
| 211 | Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders. <i>European Journal of Neurology</i> , 2016, 23, 190-195.                            | 3.3 | 41        |
| 212 | Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 108-115.                                  | 2.2 | 22        |
| 213 | Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. <i>Neurological Sciences</i> , 2016, 37, 1785-1792. | 1.9 | 23        |
| 214 | Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform. , 2016, 2016, 663-666.   |     | 30        |
| 215 | Tremor UPDRS estimation in home environment. , 2016, 2016, 3642-3645.  |     | 15        |
| 216 | Cognitive decline in Parkinson's disease: the complex picture. <i>Npj Parkinson's Disease</i> , 2016, 2, 16018.  | 5.3 | 96        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | Peripheral neuropathy and levodopa therapy in Parkinson disease: novel insights. <i>European Journal of Neurology</i> , 2016, 23, 435-436.   | 3.3 | 5         |
| 218 | Levodopa-carbidopa intestinal gel treatment in patients with < 10 years of Parkinson's disease: GLORIA registry interim results. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e93-e94.  | 2.2 | 0         |
| 219 | Gastrointestinal safety of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients: GLORIA long-term registry interim results. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e96-e97.                               | 2.2 | 0         |
| 220 | Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: State of the art 10 years after marketing. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e97-e98.  | 2.2 | 0         |
| 221 | Multicenter experience of mixed deep brain stimulation implants for movement disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e105-e106.   | 2.2 | 0         |
| 222 | Determination of minimal important difference thresholds for Parkinson's disease Questionnaire-39 in advanced Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e18-e19.                                     | 2.2 | 0         |
| 223 | The First Parkinson's Disease Pain Questionnaire (King's PD Pain Quest) – an interim analysis of a multicentre study of the patient's perspective. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e41.                                  | 2.2 | 3         |
| 224 | The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature. <i>Journal of Neural Transmission</i> , 2016, 123, 241-250.  | 2.8 | 40        |
| 225 | MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016, 123, 431-438.  | 2.8 | 102       |
| 226 | Do patients with late-stage Parkinson's disease still respond to levodopa?. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 10-16.   | 2.2 | 60        |
| 227 | Therapy-resistant symptoms in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 19-30.   | 2.8 | 27        |
| 228 | Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 57-64.   | 2.8 | 117       |
| 229 | Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimulation</i> , 2016, 9, 78-85.   | 1.6 | 86        |
| 230 | Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1237-1247.  | 3.9 | 70        |
| 231 | Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. <i>Movement Disorders</i> , 2015, 30, 1148-1149.   | 3.9 | 18        |
| 232 | King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. <i>Movement Disorders</i> , 2015, 30, 1623-1631.   | 3.9 | 189       |
| 233 | A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 170-174.   | 1.5 | 19        |
| 234 | Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms – results of a double-blind, randomized, placebo-controlled trial. <i>European Journal of Neurology</i> , 2015, 22, 1400-1407. | 3.3 | 66        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 235 | The Neural Correlates of Spatial and Object Working Memory in Elderly and Parkinson's Disease Subjects. Behavioural Neurology, 2015, 2015, 1-10.  | 2.1  | 18        |
| 236 | The "Gender Factor" in Wearing-Off among Patients with Parkinson's Disease: A Post Hoc Analysis of DEEP Study. Scientific World Journal, The, 2015, 2015, 1-10.   | 2.1  | 59        |
| 237 | Overground robot assisted gait trainer for the treatment of drug-resistant freezing of gait in Parkinson disease. Journal of the Neurological Sciences, 2015, 355, 75-78.   | 0.6  | 24        |
| 238 | "Gunslinger's gait": a new cause of unilaterally reduced arm swing. BMJ, The, 2015, 351, h6141.   | 6.0  | 14        |
| 239 | The efficacy of oral adenosine A <sub>2A</sub> antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. Expert Review of Neurotherapeutics, 2015, 15, 1383-1390.  | 2.8  | 32        |
| 240 | Eurobservational Study of Olanzapine and Risperidone in Parkinson's Disease. Movement Disorders, 2015, 30, 510-516.   | 3.9  | 203       |
| 241 | The Face Behind the Mask: Can Imaging Help Early Parkinson Diagnosis?. Movement Disorders Clinical Practice, 2015, 2, 1-2.  | 1.5  | 0         |
| 242 | Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism and Related Disorders, 2015, 21, 231-235.                              | 2.2  | 118       |
| 243 | Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Movement Disorders, 2015, 30, 150-159.   | 3.9  | 92        |
| 244 | Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. Neurological Sciences, 2015, 36, 935-943.   | 1.9  | 6         |
| 245 | Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. Expert Review of Neurotherapeutics, 2015, 15, 207-213.  | 2.8  | 12        |
| 246 | Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. Movement Disorders, 2015, 30, 688-695.   | 3.9  | 83        |
| 247 | Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism and Related Disorders, 2015, 21, 1133-1144. | 2.2  | 156       |
| 248 | Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. Parkinsonism and Related Disorders, 2015, 21, 644-649.   | 2.2  | 81        |
| 249 | The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. Parkinsonism and Related Disorders, 2015, 21, 287-291.   | 2.2  | 93        |
| 250 | Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "freezing of gait. Neurological Sciences, 2015, 36, 1683-1686.   | 1.9  | 25        |
| 251 | Targeting pain in Parkinson's disease. Lancet Neurology, The, 2015, 14, 1144-1145.  | 10.2 | 19        |
| 252 | A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. European Journal of Neurology, 2015, 22, 1184-1191.  | 3.3  | 75        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 253 | Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1273-1277.                         | 2.2  | 24        |
| 254 | Double-blind Randomized Trial of $\hat{A}$ t-DCS $\hat{A}$ versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive $\hat{A}$ Training. <i>Brain Stimulation</i> , 2015, 8, 1223-1225.                  | 1.6  | 55        |
| 255 | Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1393-1397.   | 2.2  | 33        |
| 256 | Novel formulations and modes of delivery of levodopa. <i>Movement Disorders</i> , 2015, 30, 114-120.  | 3.9  | 76        |
| 257 | Therapeutic strategies to prevent and manage dyskinesias in Parkinson $\hat{A}$ ™s disease. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 281-294.   | 2.4  | 53        |
| 258 | Grey Matter Changes in Cognitively Impaired Parkinson's Disease Patients. <i>PLoS ONE</i> , 2014, 9, e85595.  | 2.5  | 69        |
| 259 | Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 156.  | 3.7  | 150       |
| 260 | Dermoscopic features and follow $\hat{A}$ up changes of acral melanocytic naevi in childhood and adolescence. <i>British Journal of Dermatology</i> , 2014, 170, 374-381.   | 1.5  | 12        |
| 261 | Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 32-36.  | 2.2  | 16        |
| 262 | Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 394-399.   | 2.2  | 82        |
| 263 | Novel levodopa formulations in the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 143-149.   | 2.8  | 24        |
| 264 | Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.                    | 3.9  | 193       |
| 265 | Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 217-221.  | 2.2  | 25        |
| 266 | Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 27-31.   | 2.2  | 73        |
| 267 | Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurology</i> , The, 2014, 13, 141-149. | 10.2 | 547       |
| 268 | Early DEtection of wEaring off in Parkinson disease: The DEEP study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 204-211.   | 2.2  | 121       |
| 269 | The MTHFR C677T polymorphism modifies age at onset in Parkinson $\hat{A}$ ™s disease. <i>Neurological Sciences</i> , 2014, 35, 73-77.   | 1.9  | 9         |
| 270 | Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1329-1334.  | 2.2  | 64        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 271 | Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1231-1235.   | 2.2  | 76        |
| 272 | Adenosine A2A receptor antagonists in Parkinson's disease: still in the running. <i>Lancet Neurology</i> , The, 2014, 13, 748-749.   | 10.2 | 18        |
| 273 | Buckwheat achenes antioxidant profile modulates <i>Aspergillus flavus</i> growth and aflatoxin production. <i>International Journal of Food Microbiology</i> , 2014, 189, 1-10.  | 4.7  | 40        |
| 274 | Validation of the Italian version of Parkinson's Disease-Cognitive Rating Scale (PD-CRS). <i>Neurological Sciences</i> , 2014, 35, 537-544.  | 1.9  | 17        |
| 275 | Can dopamine transporter imaging define early PD?. <i>Nature Reviews Neurology</i> , 2014, 10, 432-433.  | 10.1 | 10        |
| 276 | Reasons for hospitalization in Parkinson's disease: A case-control study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 488-492.   | 2.2  | 42        |
| 277 | Multiple system atrophy as emerging template for accelerated drug discovery in $\alpha$ -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 793-799.   | 2.2  | 18        |
| 278 | Validation of the Italian version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , 2013, 34, 683-687.   | 1.9  | 123       |
| 279 | Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features. <i>Neurological Sciences</i> , 2013, 34, 621-627.   | 1.9  | 21        |
| 280 | Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , 2013, 260, 2701-2714.  | 3.6  | 128       |
| 281 | Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. <i>Journal of Neurology</i> , 2013, 260, 1731-1742.   | 3.6  | 23        |
| 282 | Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. <i>Journal of Neurology</i> , 2013, 260, 1132-1135.   | 3.6  | 10        |
| 283 | Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease. <i>Neurological Sciences</i> , 2013, 34, 1751-1758.   | 1.9  | 12        |
| 284 | Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. <i>Journal of Neural Transmission</i> , 2013, 120, 1553-1558.   | 2.8  | 59        |
| 285 | A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. <i>Journal of Neural Transmission</i> , 2013, 120, 613-618.   | 2.8  | 75        |
| 286 | Adherence to anti-Parkinson drug therapy in the REASON sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the Morisky Medical Adherence scale-8 items. <i>Neurological Sciences</i> , 2013, 34, 2015-2022. | 1.9  | 29        |
| 287 | Effects of rotigotine on Parkinson's disease-related sleep disturbances. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2571-2580.   | 1.8  | 7         |
| 288 | Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1130-1135.  | 2.2  | 16        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 289 | Rapid onset of efficacy of rasagiline in early Parkinson's disease. <i>Neurological Sciences</i> , 2013, 34, 2007-2013.   | 1.9 | 4         |
| 290 | EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 16-34.   | 3.3 | 460       |
| 291 | Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 253-259.   | 3.6 | 62        |
| 292 | Is there room for new non-dopaminergic treatments in Parkinson's disease?. <i>Journal of Neural Transmission</i> , 2013, 120, 349-352.  | 2.8 | 5         |
| 293 | Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 557-559.                               | 2.2 | 33        |
| 294 | Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 627-633.       | 2.8 | 48        |
| 295 | Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 501-507.                        | 2.2 | 99        |
| 296 | Spinal Cord Stimulation for the Treatment of Sensory Symptoms in Advanced Parkinson's Disease. <i>Neuromodulation</i> , 2013, 16, 276-279.  | 0.8 | 40        |
| 297 | Dopaminergic treatment and nonmotor features of Parkinson disease. <i>Neurology</i> , 2013, 80, 784-785.  | 1.1 | 14        |
| 298 | Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 660-665.                               | 2.2 | 112       |
| 299 | Diagnosis of possible Mild Cognitive Impairment in Parkinson's disease: Validity of the SCOPA-Cog. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1160-1163.                           | 2.2 | 24        |
| 300 | Dopaminergic treatment and nonmotor features of Parkinson disease: The horse lives. <i>Neurology</i> , 2013, 81, 854-855.   | 1.1 | 1         |
| 301 | A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. <i>PLoS ONE</i> , 2013, 8, e57221.                   | 2.5 | 95        |
| 302 | Anatomical Correlates of Cognitive Functions in Early Parkinson's Disease Patients. <i>PLoS ONE</i> , 2013, 8, e64222.  | 2.5 | 47        |
| 303 | Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease-in Parkinson's disease-Cognition (SCOPA-Cog). <i>Functional Neurology</i> , 2013, 28, 121-5. | 1.3 | 5         |
| 304 | Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 205-207.  | 0.7 | 51        |
| 305 | Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 76-82.   | 1.9 | 82        |
| 306 | Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S120-S122.   | 2.2 | 18        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 307 | 2.135 CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF PERIODS IN PARKINSON'S DISEASE: AN INTERNATIONAL STUDY. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S110.   | 2.2  | 2         |
| 308 | Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 1639-1647.   | 3.6  | 211       |
| 309 | The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012, 259, 2621-2631.   | 3.6  | 188       |
| 310 | Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. <i>Neurological Sciences</i> , 2012, 33, 1319-1327. | 1.9  | 25        |
| 311 | Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 397-399.  | 2.2  | 61        |
| 312 | The relationship between cerebral vascular disease and parkinsonism: The VADO study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 775-780.  | 2.2  | 58        |
| 313 | High-rate production of functional nanostructured films and devices by coupling flame spray pyrolysis with supersonic expansion. <i>Nanotechnology</i> , 2012, 23, 185603.   | 2.6  | 23        |
| 314 | Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012, 33, 585-593.  | 1.9  | 18        |
| 315 | Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. <i>Neurological Sciences</i> , 2012, 33, 689-694.                     | 1.9  | 18        |
| 316 | Validation of a home environment test battery for supporting assessments in advanced Parkinson's disease. <i>Neurological Sciences</i> , 2012, 33, 831-838.  | 1.9  | 13        |
| 317 | Exploring composites based on PPO blend as ablative thermal protection systems – Part II: The role of equiaxial fillers. <i>Composite Structures</i> , 2012, 94, 1060-1066.  | 5.8  | 10        |
| 318 | Movement disorders: towards new therapies in Parkinson's disease. <i>Lancet Neurology</i> , The, 2012, 11, 7-8.  | 10.2 | 1         |
| 319 | Intrathecal application of autologous bone marrow cell preparations in parkinsonian syndromes. <i>Movement Disorders</i> , 2012, 27, 1552-1555.  | 3.9  | 5         |
| 320 | Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the $\alpha$ -synuclein gene. <i>Journal of Neurology</i> , 2012, 259, 165-167.   | 3.6  | 25        |
| 321 | Repetitive transcranial magnetic stimulation in the treatment of dystonia. , 2012, , 501-511.  |      | 2         |
| 322 | Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. <i>Functional Neurology</i> , 2012, 27, 147-54.  | 1.3  | 31        |
| 323 | Pharmacokinetic evaluation of pramipexole. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1307-1314.   | 3.3  | 20        |
| 324 | Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. <i>Journal of the Neurological Sciences</i> , 2011, 310, 64-69.   | 0.6  | 70        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 325 | Parkinson's disease tremor-related metabolic network: Characterization, progression, and treatment effects. <i>NeuroImage</i> , 2011, 54, 1244-1253.  | 4.2  | 216       |
| 326 | Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011, 43, 699-705.   | 21.4 | 502       |
| 327 | Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .  |      | 6         |
| 328 | Cortical visual evoked potentials recorded after optic tract near field stimulation during GPI-DBS in non-cooperative patients. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 119-122.            | 1.4  | 9         |
| 329 | Parkinson's disease: The non-motor issues. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 717-723.   | 2.2  | 313       |
| 330 | Bladder Dysfunction. , 2011, , 67-72.   |      | 0         |
| 331 | Regression of Cardiac Valvulopathy Related to Ergot-Derived Dopamine Agonists. <i>Cardiovascular Therapeutics</i> , 2011, 29, 404-410.  | 2.5  | 17        |
| 332 | The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project. <i>Parkinson's Disease</i> , 2011, 2011, 1-7.       | 1.1  | 13        |
| 333 | Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 297.                     | 2.2  | 16        |
| 334 | Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. <i>PLoS ONE</i> , 2011, 6, e18301.   | 2.5  | 84        |
| 335 | Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). <i>Archives of Neurology</i> , 2011, 68, 223-30.   | 4.5  | 83        |
| 336 | miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. <i>Cell Death and Differentiation</i> , 2011, 18, 1628-1639.                         | 11.2 | 399       |
| 337 | Low scan rate DSC study of the monoclinic-tetragonal transition in zirconia. <i>Thermochimica Acta</i> , 2011, 524, 18-22.  | 2.7  | 7         |
| 338 | The conundrum of neuroprotection in Parkinson's disease. <i>Lancet Neurology</i> , The, 2011, 10, 396-397.  | 10.2 | 1         |
| 339 | Pathological gambling in Parkinson's disease: disease related or drug related?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 809-814.  | 2.8  | 7         |
| 340 | A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. <i>Journal of Neurology</i> , 2011, 258, 579-585.          | 3.6  | 113       |
| 341 | What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?. <i>Journal of Neural Transmission</i> , 2011, 118, 907-914. | 2.8  | 21        |
| 342 | Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: A path modeling analysis. <i>Movement Disorders</i> , 2011, 26, 225-233.                       | 3.9  | 109       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 343 | Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 464-468.  | 3.9  | 139       |
| 344 | Wearing-off scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2169-2175.   | 3.9  | 101       |
| 345 | Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect. <i>Journal of Parkinson's Disease</i> , 2011, 1, 197-203. | 2.8  | 107       |
| 346 | Parkinsonian Tremor. , 2011, , 64-72.   |      | 0         |
| 347 | Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations. <i>Clinical Neuropharmacology</i> , 2010, 33, 61-66.                                      | 0.7  | 14        |
| 348 | Levodopa in the treatment of Parkinson's disease: an old drug still going strong. <i>Clinical Interventions in Aging</i> , 2010, 5, 229.  | 2.9  | 194       |
| 349 | Single-Photon Emission Computed Tomography in Diagnosis and Differential Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 319-329.  | 1.4  | 17        |
| 350 | Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.   | 3.6  | 140       |
| 351 | Cognitive status of patients with Parkinson's disease and pathological gambling. <i>Journal of Neurology</i> , 2010, 257, 247-252.  | 3.6  | 49        |
| 352 | The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. <i>Journal of Neurology</i> , 2010, 257, 1882-1889.   | 3.6  | 39        |
| 353 | Continuous dopaminergic delivery in Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 305-308.  | 3.6  | 18        |
| 354 | Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. <i>Neurological Sciences</i> , 2010, 31, 35-40.  | 1.9  | 40        |
| 355 | Imaging for early differential diagnosis of parkinsonism. <i>Lancet Neurology</i> , The, 2010, 9, 130-131.  | 10.2 | 10        |
| 356 | Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. <i>Neurobiology of Disease</i> , 2010, 39, 98-104.   | 4.4  | 136       |
| 357 | Surgical, Medical, and Hardware Adverse Events in a Series of 141 Patients Undergoing Subthalamic Deep Brain Stimulation for Parkinson Disease. <i>World Neurosurgery</i> , 2010, 73, 338-344.                            | 1.3  | 77        |
| 358 | Imaging essential tremor. <i>Movement Disorders</i> , 2010, 25, 679-686.  | 3.9  | 80        |
| 359 | Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. <i>Movement Disorders</i> , 2010, 25, 50-56.  | 3.9  | 30        |
| 360 | Multilayer SiC for thermal protection system of space vehicles with decreased thermal conductivity through the thickness. <i>Journal of the European Ceramic Society</i> , 2010, 30, 1833-1840.                           | 5.7  | 38        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 361 | Sleep in Genetically Confirmed Pantothenate Kinase-Associated Neurodegeneration: A Video-Polysomnographic Study. <i>Parkinson's Disease</i> , 2010, 2010, 1-4.   | 1.1  | 9         |
| 362 | Cognitive Bizarreness in the Dream and Waking Mentation of Nonpsychotic Patients With Parkinsonâ€™s Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010, 22, 395-400.   | 1.8  | 7         |
| 363 | Role of Pramipexole in the Management of Parkinsonâ€™s Disease. <i>CNS Drugs</i> , 2010, 24, 829-841.  | 5.9  | 48        |
| 364 | Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonâ€™s Disease. <i>CNS Drugs</i> , 2010, 24, 119-129.   | 5.9  | 60        |
| 365 | SPECT Imaging in Movement Disorders. , 2010, , 140-147.  |      | 0         |
| 366 | The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 65-67. | 1.4  | 12        |
| 367 | Î±-Synuclein multiplication analysis in Italian familial Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 228-231.   | 2.2  | 36        |
| 368 | Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. <i>European Neuropsychopharmacology</i> , 2010, 20, 683-687.   | 0.7  | 27        |
| 369 | Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. <i>Functional Neurology</i> , 2010, 25, 21-5.  | 1.3  | 9         |
| 370 | Apomorphine and Levodopa Infusion Therapies for Advanced Parkinsonâ€™s Disease. <i>Journal of Movement Disorders</i> , 2009, 2, 4-9.   | 1.3  | 13        |
| 371 | A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. <i>Lancet Neurology</i> , The, 2009, 8, 929-937.   | 10.2 | 169       |
| 372 | Adherence to antiparkinson medication in a multicenter European study. <i>Movement Disorders</i> , 2009, 24, 826-832.  | 3.9  | 146       |
| 373 | Hyperhomocysteinemia in levodopaâ€treated patients with Parkinson's disease dementia. <i>Movement Disorders</i> , 2009, 24, 1028-1033.   | 3.9  | 53        |
| 374 | Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. <i>Movement Disorders</i> , 2009, 24, 1468-1474.   | 3.9  | 233       |
| 375 | The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.   | 3.9  | 1,171     |
| 376 | Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. <i>Journal of Neurology</i> , 2009, 256, 910-915.   | 3.6  | 61        |
| 377 | Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: A prospective case-control study. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 140-146.  | 1.4  | 40        |
| 378 | Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 327-328.  | 2.2  | 32        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 379 | Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaithâ€“Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 576-581. | 2.2 | 45        |
| 380 | Spect imaging biomarkers. <i>Journal of the Neurological Sciences</i> , 2009, 283, 268.  | 0.6 | 0         |
| 381 | Behavioural Adverse Effects of Dopaminergic Treatments in Parkinson's Disease. <i>Drug Safety</i> , 2009, 32, 475-488.   | 3.2 | 80        |
| 382 | Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 859-867.   | 2.8 | 76        |
| 383 | O.058 Will continuous dopamine stimulation prevent motor complications?. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S15.  | 2.2 | 0         |
| 384 | P1.229 Improvement of motor and non-motor symptoms after switching from oral therapy to continuous duodenal levodopa infusion in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S88.  | 2.2 | 1         |
| 385 | Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S97-S100.   | 2.2 | 64        |
| 386 | Imaging evidence supports a link between essential tremor and Parkinson's disease. <i>Nuclear Medicine Communications</i> , 2009, 30, 93-94.   | 1.1 | 7         |
| 387 | Non-motor Symptoms in Parkinson's Disease. <i>European Neurological Review</i> , 2009, 4, 25.  | 0.5 | 3         |
| 388 | Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study. <i>European Journal of Neurology</i> , 2008, 15, 22-28.   | 3.3 | 18        |
| 389 | The PRIAMO study: background, methods and recruitment. <i>Neurological Sciences</i> , 2008, 29, 61-65.   | 1.9 | 28        |
| 390 | Dopamine agonist-based strategies in the treatment of Parkinson's disease. <i>Neurological Sciences</i> , 2008, 29, 371-374.   | 1.9 | 25        |
| 391 | Clinical experience of tolcapone in advanced Parkinson's disease. <i>Neurological Sciences</i> , 2008, 29, 380-382.  | 1.9 | 7         |
| 392 | Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. <i>Neurological Sciences</i> , 2008, 29, 387-388.  | 1.9 | 23        |
| 393 | The rationale for improved integration between home care and neurology hospital services in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , 2008, 29, 392-396.  | 1.9 | 14        |
| 394 | Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [ <sup>123</sup> I]β-CIT SPECT study. <i>Journal of Neural Transmission</i> , 2008, 115, 721-729.   | 2.8 | 53        |
| 395 | The relationship between impulsivity and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 411-415.  | 3.9 | 131       |
| 396 | [ <sup>123</sup> I]β-CIT SPET imaging in drug-induced Parkinsonism. <i>Movement Disorders</i> , 2008, 23, 1825-1829.   | 3.9 | 47        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 397 | Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. <i>Movement Disorders</i> , 2008, 23, 2049-2054.   | 3.9  | 35        |
| 398 | Cost-effectiveness of <sup>123</sup> I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. <i>Movement Disorders</i> , 2008, 23, 2202-2209.                     | 3.9  | 51        |
| 399 | PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008, 29, 565-565.   | 2.5  | 74        |
| 400 | Unraveling depression in Parkinson's disease. <i>European Journal of Neurology</i> , 2008, 15, 885-886.  | 3.3  | 13        |
| 401 | A voxel-based PET study of dopamine transporters in Parkinson's disease: Relevance of age at onset. <i>Neurobiology of Disease</i> , 2008, 31, 102-109.  | 4.4  | 24        |
| 402 | MoSi2 laminate processed by tape casting: Microstructure and mechanical properties' investigation. <i>Intermetallics</i> , 2008, 16, 758-768.  | 3.9  | 14        |
| 403 | How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 266-267.         | 2.2  | 0         |
| 404 | Parkin analysis in early onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 326-333.   | 2.2  | 42        |
| 405 | Pain as a Nonmotor Symptom of Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1191-4.  | 4.5  | 208       |
| 406 | Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2008, 5, 244-246.   | 1.4  | 93        |
| 407 | Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1604-11.  | 4.5  | 127       |
| 408 | Single photon-emission computed tomography imaging in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1853-1864.   | 2.8  | 4         |
| 409 | Striatal dopamine transporter abnormalities in patients with essential tremor. <i>Nuclear Medicine Communications</i> , 2008, 29, 349-353.   | 1.1  | 69        |
| 410 | COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1. | 2.2  | 85        |
| 411 | <title>Fabrication of devices for channeling-based high-energy micro-beams</title>. , 2007, , .  |      | 0         |
| 412 | Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2007, 356, 39-46.  | 27.0 | 824       |
| 413 | <title>Silicon micromachining techniques as a tool to fabricate channeling-based devices</title>. , 2007, , .  |      | 0         |
| 414 | [ <sup>123</sup> I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. <i>NeuroReport</i> , 2007, 18, 1499-1502.   | 1.2  | 59        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 415 | Anatomical identification of active contacts in subthalamic deep brain stimulation. World Neurosurgery, 2007, 67, 140-146.   | 1.3 | 35        |
| 416 | Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: An ECD-SPECT study. Parkinsonism and Related Disorders, 2007, 13, 290-294.  | 2.2 | 61        |
| 417 | How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism and Related Disorders, 2007, 13, 528-531.                                 | 2.2 | 77        |
| 418 | Continuous dopaminergic stimulationâ€”From theory to clinical practice. Parkinsonism and Related Disorders, 2007, 13, S24-S28.   | 2.2 | 39        |
| 419 | New strategies in motor parkinsonism. Parkinsonism and Related Disorders, 2007, 13, S446-S449.   | 2.2 | 12        |
| 420 | 1.018 Loss of thalamic serotonin transporters in early-stage, drug-naïve Parkinson's disease patients is associated with tremor: A [ <sup>123</sup> I]Î²-CIT SPECT study. Parkinsonism and Related Disorders, 2007, 13, S32. | 2.2 | 1         |
| 421 | 1.164 Psychiatric symptoms in Parkinson's disease: An assessment in 486 Italian patients. Parkinsonism and Related Disorders, 2007, 13, S50.   | 2.2 | 0         |
| 422 | 1.166 Diagnosis of personality structure and cognition in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S50-S51.  | 2.2 | 0         |
| 423 | 2.214 Tolcapone treatment fluctuating patients with Parkinson's disease who did not benefit from entacapone. Parkinsonism and Related Disorders, 2007, 13, S101.   | 2.2 | 0         |
| 424 | 2.220 Duodenal levodopa infusion for advanced Parkinson's disease: 24-month treatment outcome. Parkinsonism and Related Disorders, 2007, 13, S103.   | 2.2 | 0         |
| 425 | 2.262 Adherence to antiparkinson medication in a multi-centre European study.. Parkinsonism and Related Disorders, 2007, 13, S115.   | 2.2 | 0         |
| 426 | What you always wanted to know about â€¦ The newest therapeutical strategies. Parkinsonism and Related Disorders, 2007, 13, S152.  | 2.2 | 0         |
| 427 | Whole gene deletion and splicing mutations expand thePINK1 genotypic spectrum. Human Mutation, 2007, 28, 98-98.  | 2.5 | 66        |
| 428 | Extradural motor cortex stimulation in Parkinson's disease. Movement Disorders, 2007, 22, 111-114.   | 3.9 | 46        |
| 429 | Neuropathology of Parkinson's disease associated with theLRRK2 Ile1371Val mutation. Movement Disorders, 2007, 22, 275-278.   | 3.9 | 46        |
| 430 | Duodenal levodopa infusion for advanced Parkinson's disease: 12â€”month treatment outcome. Movement Disorders, 2007, 22, 1145-1149.  | 3.9 | 241       |
| 431 | Role of DATâ€”SPECT in the diagnostic work up of Parkinsonism. Movement Disorders, 2007, 22, 1229-1238.  | 3.9 | 206       |
| 432 | Dopa-responsive pseudo-orthostatic tremor in parkinsonism. Movement Disorders, 2007, 22, 1652-1656.  | 3.9 | 44        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 433 | Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. <i>European Journal of Neurology</i> , 2007, 14, 070206022829003-???                                    | 3.3  | 11        |
| 434 | Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor. <i>European Journal of Neurology</i> , 2007, 14, 944-946.  | 3.3  | 14        |
| 435 | Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. <i>Lancet Neurology</i> , The, 2007, 6, 826-829.  | 10.2 | 231       |
| 436 | Bioactive Sulforaphane from in vitro Propagated Brassica Seedlings. <i>Engineering in Life Sciences</i> , 2007, 7, 275-277.  | 3.6  | 1         |
| 437 | Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. <i>Neurogenetics</i> , 2007, 8, 103-109.   | 1.4  | 35        |
| 438 | Daytime somnolence and night sleep disturbances in Parkinson's disease: background and future treatment prospective. <i>Neurological Sciences</i> , 2007, 28, S6-S8.   | 1.9  | 4         |
| 439 | The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 287-92.                           | 2.2  | 7         |
| 440 | Parkinson's disease, chronic hydrocarbon exposure and striatal neuronal damage: A 1-H MRS study. <i>NeuroToxicology</i> , 2006, 27, 164-168.   | 3.0  | 24        |
| 441 | Clinical correlates and cognitive underpinnings of verbal fluency impairment after chronic subthalamic stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 289-295.                        | 2.2  | 85        |
| 442 | LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 410-419.                               | 2.2  | 106       |
| 443 | BILATERAL SUBTHALAMIC DEEP BRAIN STIMULATION IN A PATIENT WITH PARKINSON'S DISEASE WHO HAD PREVIOUSLY UNDERGONE THALAMOTOMY AND AUTOLOGOUS ADRENAL GRAFTING IN THE CAUDATE NUCLEUS. <i>Neurosurgery</i> , 2006, 59, E1140-E1140. | 1.1  | 6         |
| 444 | Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006, 14, 322-331.  | 2.8  | 152       |
| 445 | Channeling-based collimators for generation of microbeams produced by silicon micromachining technology. <i>Nuclear Instruments &amp; Methods in Physics Research B</i> , 2006, 252, 11-15.                                      | 1.4  | 1         |
| 446 | Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. <i>Journal of Neurology</i> , 2006, 253, 601-607.   | 3.6  | 250       |
| 447 | Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease. <i>Neurological Sciences</i> , 2006, 27, 397-401.  | 1.9  | 40        |
| 448 | Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: Case report. <i>Movement Disorders</i> , 2006, 21, 270-273.  | 3.9  | 43        |
| 449 | Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. <i>Movement Disorders</i> , 2006, 21, 417-418.                             | 3.9  | 28        |
| 450 | Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life. <i>Movement Disorders</i> , 2006, 21, 1119-1122.                                       | 3.9  | 101       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 451 | Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. <i>Movement Disorders</i> , 2006, 21, 1144-1147.   | 3.9 | 41        |
| 452 | Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 450-453. | 1.9 | 130       |
| 453 | Tailoring of silicon crystals for relativistic-particle channeling. <i>Nuclear Instruments &amp; Methods in Physics Research B</i> , 2005, 234, 40-46.   | 1.4 | 41        |
| 454 | Novel parkin mutations detected in patients with early-onset Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 424-431.   | 3.9 | 60        |
| 455 | Brain SPECT imaging in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2005, 112, 1635-1645.  | 2.8 | 50        |
| 456 | [ <sup>123</sup> I]FP-CIT SPECT findings in two patients with Hallervorden-Spatz disease with homozygous mutation in the PANK2 gene. <i>Neurology</i> , 2005, 64, 167-168.   | 1.1 | 14        |
| 457 | The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. <i>Journal of Medical Genetics</i> , 2005, 42, e65-e65.  | 3.2 | 178       |
| 458 | Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. <i>Neurology</i> , 2005, 65, 1971-1973.  | 1.1 | 36        |
| 459 | Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes. <i>Neurology</i> , 2005, 65, 87-95.  | 1.1 | 323       |
| 460 | DN1 ECONOMIC EVALUATION OF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY. <i>Value in Health</i> , 2005, 8, A14.  | 0.3 | 2         |
| 461 | PNL16 THE ECONOMIC BURDEN OF PARKINSONISM IN ITALY. <i>Value in Health</i> , 2005, 8, A133.  | 0.3 | 0         |
| 462 | Pharmacological and PET studies in patients with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications. <i>Journal of Neural Transmission</i> , 2004, 111, 497-509.  | 2.8 | 19        |
| 463 | Pramipexole-treated Parkinson's disease during pregnancy. <i>Movement Disorders</i> , 2004, 19, 1114-1115.   | 3.9 | 41        |
| 464 | The effect of doping LiMn <sub>2</sub> O <sub>4</sub> spinel on its use as a cathode in Li-ion batteries: neutron diffraction and electrochemical studies. <i>Journal of Physics and Chemistry of Solids</i> , 2004, 65, 29-37.  | 4.0 | 39        |
| 465 | CONTINUOUS APOMORPHINE INFUSION (CAI) AND NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE: A FOLLOW-UP OF TWO YEARS. <i>Archives of Gerontology and Geriatrics</i> , 2004, 38, 291-296.   | 3.0 | 53        |
| 466 | Deep brain stimulation and its effect on sleep in Parkinson's disease. <i>Sleep Medicine</i> , 2004, 5, 211-214.   | 1.6 | 28        |
| 467 | PET and SPECT functional imaging in Parkinson's disease. <i>Sleep Medicine</i> , 2004, 5, 201-206.   | 1.6 | 36        |
| 468 | Evaluation of cefepime kinetic variables and milk production volume in goats. <i>Arquivo Brasileiro De Medicina Veterinaria E Zootecnia</i> , 2004, 56, 116-118.   | 0.4 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 469 | MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. <i>American Journal of Neuroradiology</i> , 2004, 25, 927-32.  | 2.4 | 97        |
| 470 | <sup>123</sup> I-iodoflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>Neurological Sciences</i> , 2003, 24, 149-150.   | 1.9 | 146       |
| 471 | Brain flow changes before and after deep brain stimulation of the subthalamic nucleus in Parkinson's disease. <i>Neurological Sciences</i> , 2003, 24, 151-152.   | 1.9 | 18        |
| 472 | Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , 2003, 24, 174-175.   | 1.9 | 39        |
| 473 | Deep brain stimulation for the treatment of Parkinson's disease: the experience of the Neurosurgical Department in Monza. <i>Neurological Sciences</i> , 2003, 24, s43-s44.   | 1.9 | 23        |
| 474 | <title>Detectability by photoacoustic spectroscopy of x-ray-induced ethylene emission in mice breath</title>. , 2003, , .   |     | 2         |
| 475 | MRI indirect stereotactic targeting for deep brain stimulation in Parkinson's disease. <i>Journal of Neurosurgical Sciences</i> , 2003, 47, 26-32.  | 0.6 | 8         |
| 476 | Functional neuroimaging (PET and SPECT) in the selection and assessment of patients with Parkinson's disease undergoing deep brain stimulation. <i>Journal of Neurosurgical Sciences</i> , 2003, 47, 40-6.  | 0.6 | 12        |
| 477 | Thin Section MR Study of the Basal Ganglia in the Differential Diagnosis Between Striatonigral Degeneration and Parkinson Disease. <i>Journal of Computer Assisted Tomography</i> , 2002, 26, 266-271.  | 0.9 | 49        |
| 478 | The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using <sup>11</sup> C-2- $\beta$ -carbomethoxy-3- $\beta$ -(4-fluorophenyl)-tropane in patients with movement disorders. <i>Nuclear Medicine Communications</i> , 2002, 23, 1047-1055. | 1.1 | 21        |
| 479 | <sup>99m</sup> Tc ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , 2002, 17, 1265-1270.   | 3.9 | 86        |
| 480 | Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [ <sup>11</sup> C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2). <i>Neurological Sciences</i> , 2002, 23, s51-s52.                        | 1.9 | 17        |
| 481 | Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. <i>Neurological Sciences</i> , 2002, 23, s59-s60.  | 1.9 | 40        |
| 482 | Geometrically Nonlinear Cantilever under Stochastic Loading Vectors. <i>Nonlinear Dynamics</i> , 2002, 28, 83-102.  | 5.2 | 9         |
| 483 | Infusion of nerve growth factor (NGF) into kitten visual cortex increases immunoreactivity for NGF, NGF receptors, and choline acetyltransferase in basal forebrain without affecting ocular dominance plasticity or column development. <i>Neuroscience</i> , 2001, 108, 569-585.                | 2.3 | 25        |
| 484 | Morbo di Parkinson, esposizione a sostanze tossiche e nuclei della base Uno studio mediante spettroscopia protonica a risonanza magnetica. <i>The Neuroradiology Journal</i> , 2001, 14, 47-48.   | 0.1 | 1         |
| 485 | Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. <i>Neurological Sciences</i> , 2001, 22, 45-46.   | 1.9 | 57        |
| 486 | The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [ <sup>11</sup> C]FE-CIT. <i>Neurological Sciences</i> , 2001, 22, 47-48.   | 1.9 | 78        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 487 | A morphological study of SEI film on graphite electrodes. <i>Journal of Power Sources</i> , 2001, 97-98, 146-150.  | 7.8 | 35        |
| 488 | Emergence of ocular dominance columns in cat visual cortex by 2 weeks of age. <i>Journal of Comparative Neurology</i> , 2001, 430, 235-249.  | 1.6 | 113       |
| 489 | Factors shaping the corpus callosum. <i>Journal of Comparative Neurology</i> , 2001, 433, 437-440.   | 1.6 | 14        |
| 490 | Functional correlates of pallidal stimulation for Parkinson's disease. <i>Annals of Neurology</i> , 2001, 49, 155-164.   | 5.3 | 107       |
| 491 | Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. <i>Brain</i> , 2001, 124, 1601-1609.                 | 7.6 | 133       |
| 492 | Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. <i>Journal of Nuclear Medicine</i> , 2001, 42, 1591-5.   | 5.0 | 139       |
| 493 | Benzodiazepine receptor binding in Huntington's disease: [11C]Flumazenil uptake measured using positron emission tomography. <i>Annals of Neurology</i> , 2000, 47, 644-648.                         | 5.3 | 62        |
| 494 | Tolerability of paroxetine in Parkinson's disease: A prospective study. <i>Movement Disorders</i> , 2000, 15, 986-989.   | 3.9 | 107       |
| 495 | Wild-Type p53 Gene Transfer Inhibits Invasion and Reduces Matrix Metalloproteinase-2 Levels in p53-Mutated Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2000, 114, 1188-1194. | 0.7 | 40        |
| 496 | Patterns of regional brain activation associated with different forms of motor learning. <i>Brain Research</i> , 2000, 871, 127-145.   | 2.2 | 344       |
| 497 | Hydrocarbon exposure and Parkinson's disease. <i>Neurology</i> , 2000, 55, 667-673.  | 1.1 | 77        |
| 498 | The metabolic topography of essential blepharospasm. <i>Neurology</i> , 2000, 55, 673-677.   | 1.1 | 161       |
| 499 | Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. <i>Annals of Neurology</i> , 2000, 47, 644-8.                           | 5.3 | 16        |
| 500 | Increased cerebral iron uptake in Wilson's disease: a <sup>52</sup> Fe-citrate PET study. <i>Journal of Nuclear Medicine</i> , 2000, 41, 781-7.  | 5.0 | 46        |
| 501 | Anatomical Correlates of Functional Plasticity in Mouse Visual Cortex. <i>Journal of Neuroscience</i> , 1999, 19, 4388-4406.   | 3.6 | 302       |
| 502 | An overnight switch to ropinirole therapy in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 1999, 106, 925-929.  | 2.8 | 51        |
| 503 | Positron emission tomographic studies in restless legs syndrome. <i>Movement Disorders</i> , 1999, 14, 141-145.  | 3.9 | 177       |
| 504 | Reproducibility of regional metabolic covariance patterns: comparison of four populations. <i>Journal of Nuclear Medicine</i> , 1999, 40, 1264-9.  | 5.0 | 91        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 505 | Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. <i>Clinical Neuropharmacology</i> , 1999, 22, 277-80.                                     | 0.7 | 9         |
| 506 | [11C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length. <i>Annals of Neurology</i> , 1998, 43, 253-255.                            | 5.3 | 120       |
| 507 | Functional brain networks in DYT1 dystonia. <i>Annals of Neurology</i> , 1998, 44, 303-312.   | 5.3 | 302       |
| 508 | D2receptor binding in dopa-responsive dystonia. <i>Annals of Neurology</i> , 1998, 44, 758-762.   | 5.3 | 32        |
| 509 | Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. <i>Movement Disorders</i> , 1998, 13, 268-274.   | 3.9 | 105       |
| 510 | Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 147-158.     | 2.2 | 12        |
| 511 | The metabolic anatomy of tremor in Parkinson's disease. <i>Neurology</i> , 1998, 51, 803-810.   | 1.1 | 106       |
| 512 | Factors Affecting the Stabilization of Mn Spinel Capacity upon Staring and Cycling at High Temperatures. <i>Journal of the Electrochemical Society</i> , 1998, 145, 2726-2732.                        | 2.9 | 55        |
| 513 | Cerebral Glucose Metabolism in Women With Panic Disorder. <i>American Journal of Psychiatry</i> , 1998, 155, 1178-1183.   | 7.2 | 118       |
| 514 | Effect of sensory disuse on geniculate afferents to cat visual cortex. <i>Visual Neuroscience</i> , 1998, 15, 401-9.  | 1.0 | 34        |
| 515 | Morphology of Single Geniculocortical Afferents and Functional Recovery of the Visual Cortex after Reverse Monocular Deprivation in the Kitten. <i>Journal of Neuroscience</i> , 1998, 18, 9896-9909. | 3.6 | 60        |
| 516 | Brain Networks of Motor Behavior Assessed by Principal Component Analysis. , 1998, , 165-172.   |     | 4         |
| 517 | Reproducibility of Regional Metabolic Covariance Patterns: Comparison of Four Populations. , 1998, , 247-252.   |     | 46        |
| 518 | Neutral Amino Acids Influence [ 18 F]Fluorodopa Quantification 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII.. , 1998, , 379-385.                          |     | 0         |
| 519 | Dopamine transporter imaging with fluorine-18-FPCIT and PET. <i>Journal of Nuclear Medicine</i> , 1998, 39, 1521-30.  | 5.0 | 131       |
| 520 | Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. <i>Brain</i> , 1997, 120, 2187-2195.                   | 7.6 | 209       |
| 521 | Metabolic correlates of pallidal neuronal activity in Parkinson's disease. <i>Brain</i> , 1997, 120, 1315-1324.   | 7.6 | 118       |
| 522 | Lithiated MnO <sub>2</sub> Phases as Cathodes for 3 V Li and Li <sup>+</sup> Ion Cells. <i>Journal of the Electrochemical Society</i> , 1997, 144, 1553-1559.   | 2.9 | 17        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 523 | Preoperative indicators of clinical outcome following stereotaxic pallidotomy. <i>Neurology</i> , 1997, 49, 1083-1090.   | 1.1 | 56        |
| 524 | The metabolic anatomy of Tourette's syndrome. <i>Neurology</i> , 1997, 48, 927-933.  | 1.1 | 160       |
| 525 | Doped Li <sup>+</sup> Mn Spinel: Physical/Chemical Characteristics and Electrochemical Performance in Li Batteries. <i>Chemistry of Materials</i> , 1997, 9, 1443-1450.  | 6.7 | 81        |
| 526 | α6β4 and α6β1 Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines. <i>Experimental Cell Research</i> , 1997, 236, 76-85.   | 2.6 | 201       |
| 527 | Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). <i>European Neuropsychopharmacology</i> , 1997, 7, 9-24.                      | 0.7 | 320       |
| 528 | Cerebral Metabolic Changes ( <sup>18</sup> F-FDG PET) during Selective Anterior Temporal Lobe Amobarbital Test. <i>European Neurology</i> , 1997, 38, 268-275.   | 1.4 | 8         |
| 529 | Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. <i>Brain Research</i> , 1997, 767, 45-54.                 | 2.2 | 11        |
| 530 | Long-term changes of striatal dopamine D <sub>2</sub> Receptors in patients with Parkinson's disease: A study with positron emission tomography and [ <sup>11</sup> C]Raclopride. <i>Movement Disorders</i> , 1997, 12, 33-38.             | 3.9 | 215       |
| 531 | Cerebral glucose metabolism in patients with spasmodic torticollis. <i>Movement Disorders</i> , 1997, 12, 704-708.   | 3.9 | 78        |
| 532 | Temporal lobe epilepsy: Correlation of proton magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography. <i>Magnetic Resonance in Medicine</i> , 1997, 37, 18-23.  | 3.0 | 38        |
| 533 | Photoemission from atomic and molecular adsorbates on Rh(100). <i>Surface Science</i> , 1996, 347, 53-62.  | 1.9 | 39        |
| 534 | Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A. <i>Nuclear Medicine and Biology</i> , 1996, 23, 229-234.   | 0.6 | 12        |
| 535 | Radiosynthesis of [18F] N-3-fluoropropyl-2- <sup>12</sup> -carbomethoxy-3- <sup>12</sup> -(4-iodophenyl) nortropine and the first human study with positron emission tomography. <i>Nuclear Medicine and Biology</i> , 1996, 23, 999-1004. | 0.6 | 80        |
| 536 | Plasticity of geniculocortical afferents following brief or prolonged monocular occlusion in the cat. <i>Neuroscience</i> , 1996, 369, 64-82.  |     | 126       |
| 537 | Storage characteristics of cathodes for Li-ion batteries. <i>Electrochimica Acta</i> , 1996, 41, 2683-2689.  | 5.2 | 145       |
| 538 | Effect of partial Ga <sup>3+</sup> substitution for Mn <sup>3+</sup> in LiMn <sub>2</sub> O <sub>4</sub> on its behaviour as a cathode for Li cells. <i>Journal of Electroanalytical Chemistry</i> , 1996, 410, 115-118.                   | 3.8 | 27        |
| 539 | Impedance study on the reactivity of gel polymer electrolytes towards a lithium electrode. <i>Journal of Power Sources</i> , 1996, 58, 139-144.  | 7.8 | 32        |
| 540 | Striatal glucose metabolism and dopamine D <sub>2</sub> receptor binding in asymptomatic gene carriers and patients with Huntington's disease. <i>Brain</i> , 1996, 119, 2085-2095.  | 7.6 | 312       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 541 | Secondary Parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]Fluorodopa. <i>Acta Neurologica Scandinavica</i> , 1996, 93, 387-392.   | 2.1 | 28        |
| 542 | n-Hexane-induced parkinsonism: Pathogenetic hypotheses. <i>Movement Disorders</i> , 1995, 10, 279-282.   | 3.9 | 44        |
| 543 | Mapping subcortical extrarelay afferents onto primary somatosensory and visual areas in cats. <i>Journal of Comparative Neurology</i> , 1995, 362, 46-70.  | 1.6 | 22        |
| 544 | First results from the high energy resolution photoemission beam line at ELETTRA. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 1995, 364, 374-379. | 1.6 | 54        |
| 545 | Synthesis of Mn spinels from different polymorphs of MnO <sub>2</sub> . <i>Journal of Power Sources</i> , 1995, 56, 37-43.   | 7.8 | 28        |
| 546 | Complementary Positron Emission Tomographic Studies of the Striatal Dopaminergic System in Parkinson's Disease. <i>Archives of Neurology</i> , 1995, 52, 1183-1190.  | 4.5 | 169       |
| 547 | Positron emission tomography in drug evaluation: Influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-l-dopa in rhesus monkey. <i>Nuclear Medicine and Biology</i> , 1995, 22, 921-927.   | 0.6 | 15        |
| 548 | Lisuride and [C-11]-Raclopride Interaction at the D2 Receptor Site. , 1995, , 205-214.   |     | 0         |
| 549 | Ultrastructural Evidence for Synaptic Interactions between Thalamocortical Axons and Subplate Neurons. <i>European Journal of Neuroscience</i> , 1994, 6, 1729-1742.   | 2.6 | 128       |
| 550 | [ <sup>11</sup> C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease. <i>Neurology</i> , 1994, 44, 1325-1325.   | 1.1 | 188       |
| 551 | Side Effects of the Catechol-O-Methyl-Transferase Inhibitor Ro 4067592 in Rabbits. <i>Clinical Neuropharmacology</i> , 1994, 17, 270-276.  | 0.7 | 5         |
| 552 | Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. <i>Nuclear Medicine Communications</i> , 1994, 15, 806-813.   | 1.1 | 38        |
| 553 | Striatal dopamine D <sub>2</sub> receptors in patients with narcolepsy measured with PET and [ <sup>11</sup> C]-raclopride. <i>Neurology</i> , 1994, 44, 2101-2101.  | 1.1 | 33        |
| 554 | Preoperative and postoperative glucose consumption in mesiobasal and lateral temporal lobe epilepsy. <i>Neurology</i> , 1994, 44, 2125-2125.   | 1.1 | 75        |
| 555 | Treatment with D-penicillamine improves dopamine D <sub>2</sub> receptor binding and T <sub>2</sub> signal intensity in de novo Wilson's disease. <i>Neurology</i> , 1994, 44, 1079-1079.  | 1.1 | 29        |
| 556 | High Energy Resolution Photoemission Beam Line at ELETTRA. <i>Acta Physica Polonica A</i> , 1994, 86, 487-495.   | 0.5 | 1         |
| 557 | Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol. <i>Journal of Neural Transmission Supplementum</i> , 1994, 43, 123-32.                                 | 0.5 | 7         |
| 558 | Increased striatal glucose consumption in sydenham's chorea. <i>Movement Disorders</i> , 1993, 8, 437-444.   | 3.9 | 42        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 559 | A calibration bench for electro-optical characterization of CCD sensors. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 1993, 326, 150-153.                        | 1.6  | 0         |
| 560 | Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). European Journal of Clinical Pharmacology, 1993, 44, 135-140.   | 1.9  | 10        |
| 561 | Dopamine D2 Receptors in Normal Human Brain: Effect of Age Measured by Positron Emission Tomography (PET) and [11C]-Raclopridea. Annals of the New York Academy of Sciences, 1993, 695, 81-85.   | 3.8  | 73        |
| 562 | Effect of Age on D2 Dopamine Receptors in Normal Human Brain Measured by Positron Emission Tomography and 11C-Raclopride. Archives of Neurology, 1993, 50, 474-480.  | 4.5  | 170       |
| 563 | Rapid remodeling of axonal arbors in the visual cortex. Science, 1993, 260, 1819-1821.   | 12.6 | 546       |
| 564 | T <sub>2</sub> relaxation time in patients with Parkinson's disease. Neurology, 1993, 43, 697-697.   | 1.1  | 162       |
| 565 | Band offsets and strain in CdTe-GaAs heterostructures. Physical Review B, 1993, 48, 8899-8910.   | 3.2  | 26        |
| 566 | Development of individual geniculocortical arbors in cat striate cortex and effects of binocular impulse blockade. Journal of Neuroscience, 1993, 13, 3549-3573.   | 3.6  | 246       |
| 567 | Mesiobasal versus lateral temporal lobe epilepsy. Neurology, 1993, 43, 79-79.  | 1.1  | 138       |
| 568 | AlAs-GaAs heterojunction engineering by means of group-IV elemental interface layers. Physical Review B, 1992, 45, 4528-4531.  | 3.2  | 45        |
| 569 | Structure and local dipole of Si interface layers in AlAs-GaAs heterostructures. Physical Review B, 1992, 46, 6834-6845.   | 3.2  | 44        |
| 570 | Tuning AlAs-GaAs heterostructure properties by means of MBE-grown Si interface layers. Surface Science, 1991, 251-252, 82-86.  | 1.9  | 13        |
| 571 | Tuning AlAs-GaAs band discontinuities and the role of Si-induced local interface dipoles. Physical Review B, 1991, 43, 2450-2453.  | 3.2  | 123       |
| 572 | Uptake of radiocesium by mushrooms. Science of the Total Environment, 1991, 106, 183-190.  | 8.0  | 32        |
| 573 | Epilepsia partialis continua studied by PET. Epilepsy Research, 1991, 9, 44-48.  | 1.6  | 41        |
| 574 | A procedure for the simultaneous visualization of two anterograde and different retrograde fluorescent tracers. Journal of Neuroscience Methods, 1991, 38, 183-191.  | 2.5  | 18        |
| 575 | Epitaxial growth and interface parameters of Si layers on GaAs(001) and AlAs(001) substrates. Journal of Vacuum Science & Technology an Official Journal of the American Vacuum Society B, Microelectronics Processing and Phenomena, 1991, 9, 2225. | 1.6  | 30        |
| 576 | Relation Between Putative Transmitter Phenotypes and Connectivity of Subplate Neurons During Cerebral Cortical Development. European Journal of Neuroscience, 1990, 2, 744-761.  | 2.6  | 115       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 577 | Requirement for subplate neurons in the formation of thalamocortical connections. <i>Nature</i> , 1990, 347, 179-181.  | 27.8 | 561       |
| 578 | Pioneer Neurons and Target Selection in Cerebral Cortical Development. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1990, 55, 469-480.               | 1.1  | 80        |
| 579 | Effects of Terguride in Patients with Huntington's Disease. <i>Clinical Neuropharmacology</i> , 1989, 12, 435-439.   | 0.7  | 8         |
| 580 | Continuous dopaminergic stimulation in the management of complicated Parkinson's disease. <i>Mount Sinai Journal of Medicine</i> , 1988, 55, 62-6.                   | 1.9  | 0         |
| 581 | Functional organization of the anterior ectosylvian cortex in the cat. <i>Behavioural Brain Research</i> , 1987, 26, 230-230.  | 2.2  | 0         |
| 582 | Voluntary allocation of visual attention to foveal and extrafoveal sites. <i>Behavioural Brain Research</i> , 1987, 26, 240-241.                                     | 2.2  | 0         |
| 583 | Visual and somatosensory integration in the anterior ectosylvian cortex of the cat. <i>Brain Research</i> , 1987, 410, 21-31.  | 2.2  | 35        |
| 584 | Electrophysiological evidence for interhemispheric connections in the anterior ectosylvian sulcus in the cat. <i>Experimental Brain Research</i> , 1987, 66, 90-8.   | 1.5  | 12        |
| 585 | Role of Callosal Connections in the Representation of the Visual Field in the Primary Visual Cortex of the Cat. , 1987, , 349-366.                                   |      | 0         |
| 586 | Role of Callosal Connections in the Representation of the Visual Field in the Primary Visual Cortex of the Cat. , 1987, , 349-366.                                   |      | 1         |
| 587 | Mössbauer studies of the Umbria archeological clays. <i>Hyperfine Interactions</i> , 1986, 29, 1133-1136.  | 0.5  | 3         |
| 588 | Interhemispheric influences on area 19 of the cat. <i>Experimental Brain Research</i> , 1985, 59, 171-184.   | 1.5  | 27        |
| 589 | Immediate postoperative retention of visual discriminations following selective cortical lesions in the cat. <i>Behavioural Brain Research</i> , 1985, 17, 145-162.  | 2.2  | 14        |
| 590 | Radon and radon daughter evaluation in a natural radioactivity survey indoors. <i>Science of the Total Environment</i> , 1985, 45, 373-380.                          | 8.0  | 4         |
| 591 | Indoor Exposure in a Region of Central Italy. <i>Radiation Protection Dosimetry</i> , 1984, 7, 271-274.  | 0.8  | 11        |
| 592 | Binocularity in the visual cortex of the adult cat does not depend on the integrity of the corpus callosum. <i>Behavioural Brain Research</i> , 1984, 13, 183-192.   | 2.2  | 36        |
| 593 | Mössbauer Study of the Pb-Sn Te System. <i>Physica Status Solidi (B): Basic Research</i> , 1983, 120, K15.   | 1.5  | 2         |
| 594 | Physiological organization of callosal connections of a visual lateral suprasylvian cortical area in the cat. <i>Journal of Neurophysiology</i> , 1983, 49, 902-921. | 1.8  | 49        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 595 | The contribution of the corpus callosum to receptive fields in the lateral suprasylvian visual areas of the cat. Behavioural Brain Research, 1982, 4, 155-176.                          | 2.2 | 35        |
| 596 | Mössbauer study of the $Pb^{208}Sn^{119}$ $^{125}Te$ system. Physica Status Solidi (B): Basic Research, 1982, 114, 585-588.   | 1.5 | 4         |
| 597 | Differences in binocular interactions between cortical areas 17 and 18 and superior colliculus of siamese cats. Journal of Comparative Neurology, 1981, 200, 597-611.                   | 1.6 | 16        |
| 598 | Callosum-dependent binocular interactions in the lateral suprasylvian area of Siamese cats which lack binocular neurons in areas 17 and 18. Brain Research, 1980, 197, 230-235.         | 2.2 | 37        |
| 599 | Importance of corpus callosum for visual receptive fields of single neurons in cat superior colliculus. Journal of Neurophysiology, 1979, 42, 137-152.                                  | 1.8 | 47        |
| 600 | Behavioral and electrophysiological effects of unilateral optic tract section in ordinary and siamese cats. Journal of Comparative Neurology, 1979, 185, 183-202.                       | 1.6 | 15        |
| 601 | Learning and interhemispheric transfer of visual pattern discriminations following unilateral suprasylvian lesions in split-chiasm cats. Experimental Brain Research, 1979, 34, 551-74. | 1.5 | 36        |
| 602 | Indirect, across-the-midline retinotectal projections and representation of ipsilateral visual field in superior colliculus of the cat. Journal of Neurophysiology, 1978, 41, 285-304.  | 1.8 | 36        |
| 603 | Movement disorders in multiple sclerosis. , 0, , 268-278.   |     | 0         |